BICCS 2025: The impact of Mavacamten

This promotional site is only intended for UK healthcare professionals.
Adverse event reporting can be found at the bottom of the page.
This promotional site is only intended for UK healthcare professionals. Adverse event reporting can be found at the bottom of the page.
I am not a UK healthcare professional
Prescribing Information

BICCS 2025: The impact of Mavacamten on patients and ICC services with Dr Rachel Bastiaenen

Footage from the BMS Sponsored Symposium at the British Inherited Cardiovascular Conditions (BICCS) Annual Conference in December 2025. Dr. Rachel Bastiaenen shares her perspectives on the impact of Mavacamten on patients and ICC Services.

EMC, Electronic Medicines Compendium; HCM, hypertrophic cardiomyopathy; HCP, healthcare professional; ICC, Inherited Cardiac Conditions; LTE, long-term extension; LVOT, left ventricular outflow tract; MDT, multidisciplinary team; MoA, mechanism of action; oRDM, other relevant decision-maker.

3500-GB-2600240 | October 2026